Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial
<sup>177</sup>Lu-rhPSMA-10.1 delivers high radiation doses to tumours vs. normal organs, facilitated by its favourable pharmacokinetics. Cumulative doses to normal organs were well within established tolerable limits, suggesting higher cumulative radioactivity could be administered in clinical trials. The observation of decreasing tumour absorbed dose with subsequent cycles also supports the exploration of front-loading radioactivity in Phase II.
Authors
- Luke T. Nordquist
- Joseph R. Osborne (ORCID: https://orcid.org/0000-0003-0232-5960)
- Vikas Prasad
- Nathaniel Scott (ORCID: https://orcid.org/0000-0002-3650-5807)
- Hyun Kim (ORCID: https://orcid.org/0000-0002-7210-5798)
- Daniel Stevens (ORCID: https://orcid.org/0000-0003-4954-014X)
- James Nagarajah (ORCID: https://orcid.org/0000-0002-3555-0809)
- Benjamin Fongenie
Institutions
- Washington University in St. Louis (US)
- Cornell University (US)
- RCA (United States) (US)
- Blue Earth Diagnostics (United Kingdom) (GB)
- Molecular Innovations (United States) (US)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1007/s00259-025-07313-z
- Citations
- 2
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 2.72